Drug intelligence / Profile preview

MTC-896

Development stage: Phase 2
Lead developer: Mimetica
Modality: Peptides, Small Molecules
Administration: Topical

Overview

MTC-896 is a synthetic peptide and small molecule drug developed by Mimetica for dermatological conditions. It acts as an antagonist of the melanocortin receptor 5 (MC5R), a G protein-coupled receptor involved in sebum production and skin inflammation. By blocking MC5R, MTC-896 is designed to reduce sebum secretion and has been investigated primarily for the treatment of acne vulgaris and seborrheic dermatitis. The drug has reached Phase 2 clinical trials but no recent development or approval has been reported[1][2][3][4][5][7].

Other names: MC-5 antagonists (dermatological disease)

Targets

MC5R (Melanocortin 5 Receptor)

Beyond the preview

Go deeper on MTC-896.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTC-896.

Explore the full profile